ArticleCancer gene therapy2008
Anticancer activity of oncolytic adenovirus vector armed with IFN-alpha and ADP is enhanced by pharmacologically controlled expression of TRAIL.
Article in Cancer gene therapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 46 citations in OpenAlex.
- Role of Gene Therapy in Pancreatic Cancer-A Review.Cancers · 2018Review
- The Development of Oncolytic Adenovirus Therapy in the Past and Future - For the Case of Pancreatic CancerCurrent cancer drug targets · 2018Review
- Oncolytic adenovirus expressing interferon alpha in a syngeneic Syrian hamster model for the treatment of pancreatic cancer.Surgery · 2015Article
- Inducible gene expression in tumors colonized by modified oncolytic vaccinia virus strains.Journal of virology · 2014Article
- Going viral with cancer immunotherapy.Nature reviews. Cancer · 2014Review
- Highly attenuated recombinant vesicular stomatitis virus VSV-12'GFP displays immunogenic and oncolytic activity.Journal of virology · 2013Article
- Oncolytic virus therapy for cancer.Oncolytic virotherapy · 2013Review
- Generation of a novel, cyclooxygenase-2-targeted, interferon-expressing, conditionally replicative adenovirus for pancreatic cancer therapy.American journal of surgery · 2012Article
- Synthetic riboswitches for external regulation of genes transferred by replication-deficient and oncolytic adenoviruses.Nucleic acids research · 2012Article
- Increasing the efficacy of oncolytic adenovirus vectors.Viruses · 2010Article
- Analysis of adenovirus trans-complementation-mediated gene expression controlled by melanoma-specific TETP promoter in vitro.Virology journal · 2010Article
- Tumor-targeted delivery of biologically active TRAIL protein.Cancer gene therapy · 2010Article
- Current issues and future directions of oncolytic adenoviruses.Molecular therapy : the journal of the American Society of Gene Therapy · 2010Review
- Article
- Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus.Molecular therapy : the journal of the American Society of Gene Therapy · 2009Article
- Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agents.Virology · 2009Article
- "Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment.Current gene therapy · 2009Review
- Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus.Human gene therapy · 2009Article
- Cytokine determinants of viral tropism.Nature reviews. Immunology · 2009Review
- Armed replicating adenoviruses for cancer virotherapy.Cancer gene therapy · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
We have previously described oncolytic adenovirus (Ad) vectors KD3 and KD3-interferon (IFN) that were rendered cancer-specific by mutations in the E1A region of Ad; these mutations abolish binding of E1A proteins to p300/CBP and pRB. The antitumor activity of the vectors was enhanced by overexpression of the Adenovirus Death Protein (ADP, E3-11.6K) and by replication-linked expression of IFN-alpha. We hypothesized that the anticancer efficacy of the KD3-IFN vector could be further improved by expression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). E1-deleted Ad vectors were constructed carrying reporter genes for enhanced green fluorescent protein or secreted placental alkaline phosphatase (SEAP) and a therapeutic gene for TRAIL under control of the TetON system. Expression of the genes was increased in the presence of a helper virus and the inducer doxycycline such that up to 231-fold activation of expression for the TetON-SEAP vector was obtained. Coinfection with TetON-TRAIL augmented oncolytic activity of KD3 and KD3-IFN in vitro. Induction of TRAIL expression did not reduce the yield of progeny virus. Combination of TetON-TRAIL and KD3-IFN produced superior antitumor activity in vivo as compared with either vector alone demonstrating the efficacy of a four-pronged cancer gene therapy approach, which includes Ad oncolysis, ADP overexpression, IFN-alpha-mediated immunotherapy, and pharmacologically controlled TRAIL activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.